Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure
| Title: | Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure |
|---|---|
| Authors: | Packer M; McMurray JJV; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Solomon SD; Swedberg K; Zile M; Andersen K; Arango JL; Arnold JM; Belohlavek J; Bohm M; Boytsov S; Burgess LJ; Cabrera W; Calvo C; Chen CH; Dukat A; Duarte YC; Erglis A; Fu M; Gomez E; Gonzalez-Medina A; Hagege AA; Huang J; Katova T; Kiatchoosakun S; Kim KS; Kozan O; Llamas EB; Martinez F; Merkely B; Mendoza I; Mosterd A; Negrusz-Kawecka M; Peuhkurinen K; Ramires FJA; Refsgaard J; Rosenthal A; Senni M; Jr ASS; Silva-Cardoso J; Squire IB; Starling RC; Teerlink JR; Vanhaecke J; Vinereanu D; Wong RCC |
| Contributors: | Packer, M; Mcmurray, J; Desai, A; Gong, J; Lefkowitz, M; Rizkala, A; Rouleau, J; Shi, V; Solomon, S; Swedberg, K; Zile, M; Andersen, K; Arango, J; Arnold, J; Belohlavek, J; Bohm, M; Boytsov, S; Burgess, L; Cabrera, W; Calvo, C; Chen, C; Dukat, A; Duarte, Y; Erglis, A; Fu, M; Gomez, E; Gonzalez-Medina, A; Hagege, A; Huang, J; Katova, T; Kiatchoosakun, S; Kim, K; Kozan, O; Llamas, E; Martinez, F; Merkely, B; Mendoza, I; Mosterd, A; Negrusz-Kawecka, M; Peuhkurinen, K; Ramires, F; Refsgaard, J; Rosenthal, A; Senni, M; Jr, A; Silva-Cardoso, J; Squire, I; Starling, R; Teerlink, J; Vanhaecke, J; Vinereanu, D; Wong, R |
| Publisher Information: | Lippincott Williams & Wilkins; US |
| Publication Year: | 2015 |
| Collection: | Università degli Studi di Milano-Bicocca: BOA (Bicocca Open Archive) |
| Subject Terms: | Angiotensin; Heart failure; Neprilysin; Receptor |
| Description: | Background-Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk of clinical deterioration in surviving patients. Methods and Results-We compared the angiotensin-neprilysin inhibitor LCZ696 (400 mg daily) with the angiotensinconverting enzyme inhibitor enalapril (20 mg daily) in 8399 patients with heart failure and reduced ejection fraction in a double-blind trial. The analyses focused on prespecified measures of nonfatal clinical deterioration. In comparison with the enalapril group, fewer LCZ696-treated patients required intensification of medical treatment for heart failure (520 versus 604; hazard ratio, 0.84; 95% confidence interval, 0.74-0.94; P=0.003) or an emergency department visit for worsening heart failure (hazard ratio, 0.66; 95% confidence interval, 0.52-0.85; P=0.001). The patients in the LCZ696 group had 23% fewer hospitalizations for worsening heart failure (851 versus 1079; P |
| Document Type: | article in journal/newspaper |
| File Description: | STAMPA |
| Language: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/25403646; info:eu-repo/semantics/altIdentifier/wos/WOS:000347299900017; volume:131; issue:1; firstpage:54; lastpage:61; numberofpages:8; journal:CIRCULATION; https://hdl.handle.net/10281/372117 |
| DOI: | 10.1161/CIRCULATIONAHA.114.013748 |
| Availability: | https://hdl.handle.net/10281/372117; https://doi.org/10.1161/CIRCULATIONAHA.114.013748 |
| Accession Number: | edsbas.50DA3A1F |
| Database: | BASE |